AxoGen, Inc. $AXGN Shares Sold by American Century Companies Inc.

American Century Companies Inc. decreased its holdings in AxoGen, Inc. (NASDAQ:AXGN) by 10.6% in the first quarter, HoldingsChannel.com reports. The firm owned 31,206 shares of the medical equipment provider’s stock after selling 3,693 shares during the quarter. American Century Companies Inc.’s holdings in AxoGen were worth $577,000 at the end of the most recent reporting period.

A number of other large investors also recently bought and sold shares of AXGN. Driehaus Capital Management LLC raised its holdings in AxoGen by 166.0% in the 4th quarter. Driehaus Capital Management LLC now owns 954,439 shares of the medical equipment provider’s stock worth $15,729,000 after purchasing an additional 595,579 shares during the period. Invesco Ltd. raised its holdings in AxoGen by 2,124.5% in the 1st quarter. Invesco Ltd. now owns 382,429 shares of the medical equipment provider’s stock worth $7,075,000 after purchasing an additional 365,237 shares during the period. Nuveen LLC acquired a new position in AxoGen in the 1st quarter worth about $5,668,000. Balyasny Asset Management L.P. acquired a new position in AxoGen in the 4th quarter worth about $4,943,000. Finally, Informed Momentum Co LLC raised its holdings in shares of AxoGen by 558.7% during the first quarter. Informed Momentum Co LLC now owns 240,737 shares of the medical equipment provider’s stock valued at $4,454,000 after acquiring an additional 204,190 shares during the last quarter. Institutional investors and hedge funds own 80.29% of the company’s stock.

AxoGen Price Performance

NASDAQ:AXGN opened at $15.98 on Friday. AxoGen, Inc. has a one year low of $9.22 and a one year high of $21.00. The company has a debt-to-equity ratio of 0.59, a quick ratio of 2.67 and a current ratio of 4.14. The stock has a market cap of $735.24 million, a PE ratio of -159.78 and a beta of 1.03. The stock has a 50 day moving average price of $13.58 and a 200 day moving average price of $14.35.

Analyst Ratings Changes

A number of equities analysts have commented on the company. Wall Street Zen raised AxoGen from a “hold” rating to a “buy” rating in a report on Saturday, August 9th. Canaccord Genuity Group reduced their target price on AxoGen from $26.00 to $24.00 and set a “buy” rating for the company in a report on Tuesday, May 13th. Three equities research analysts have rated the stock with a Buy rating, According to data from MarketBeat, AxoGen currently has a consensus rating of “Buy” and a consensus target price of $26.00.

AxoGen Company Profile

AxoGen, Inc, together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company’s products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries.